Product Description
Efavirenz is used along with other medications to treat human immunodeficiency virus (HIV) infection. Efavirenz is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although efavirenz does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a699004.html)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: Western America
Company Founding Year: 1987
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Czech Republic, France, Netherlands, New Zealand, Poland, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: HIV Infections
Phase 1: Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Lymphoma, B-Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20222508 |
CTR20222508 | P1 |
Completed |
Lymphoma, B-Cell |
2023-01-27 |
2025-04-29 |
Patient Enrollment|Treatments |
|
2011-004038-33 |
2011-004038-33 | P3 |
Completed |
HIV Infections |
2024-12-02 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06797674 |
MK-7602-005 | P1 |
Completed |
Healthy Volunteers |
2025-08-12 |
50% |
2025-08-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT06698016 |
MK-1026-014 | P1 |
Completed |
Healthy Volunteers |
2023-10-30 |
2024-11-21 |
Primary Endpoints|Treatments |
|
ACTRN12618001838202p |
mBPaL | P1 |
Not yet recruiting |
Idiopathic Pulmonary Fibrosis |
None |